Guggenheim raised the firm’s price target on Zevra Therapeutics (ZVRA) to $22 from $20 and keeps a Buy rating on the shares. The Miplyffa launch is off to “a fast start” with U.S. sales of $10.1M for the first roughly one month of the launch, exceeding the firm’s early expectations, the analyst tells investors.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZVRA:
- Zevra Therapeutics: Promising Outlook with Strong Financials and Strategic Focus on Rare Diseases
- Zevra Therapeutics price target raised to $25 from $23 at Canaccord
- Zevra Therapeutics: Strong Buy Rating Backed by Impressive Sales and Robust Financial Position
- Zevra Therapeutics’ Earnings Call Highlights Success and Growth
- Zevra Therapeutics price target raised to $18 from $17 at Citizens JMP